Michael Yee, RBC Capital Markets biotech analyst, shares his take on big biotech movers including Mylan, Tesaro and more.
CNBC's Meg Tirrell reports the latest in biotech, including what is next for Mylan following the company's EpiPen settlement with the U.S. Department of Justice.
CNBC's Meg Tirrell reports on why billions are at stake for Bristol-Myers and Merck. The “Fast Money” traders weigh in.
Acute flaccid myelitis (AFM) — a mysterious muscle weakness, similar to polio — appears to be on the rise this year, reports NBC.
The "Fast Money Halftime Report" traders; Rob Sechan, UBS managing director; and Adam Parker, Morgan Stanley U.S. chief equity strategist, share their fourth quarter game plans.
The key biotechnology ETF fell more than 3 percent on Thursday.
Discussing why options traders are cautious about Teva Pharmaceuticals with CNBC contributor Mike Khouw.
Biotech stocks are under pressure as California proposes a "Drug Price Relief Act" to curb the high cost of drugs after Mylan's EpiPen controversy. The "Fast Money" traders share their views on the biotech sector.
Lawmakers are venting outrage over high prescription drug costs, but members might want to look in the mirror, NBC News reports.
Intra-Cellular Therapies shares plunge 68 percent after study results on a schizophrenia drug trial. CNBC's Seema Mody reports.
CNBC's Meg Tirrell looks at what could be the next drug pricing scandal.
CNBC's Meg Tirrell reports on the rising price of Naloxone and possible impacts.
Nina Tandon, EpiBone co-founder and CEO, discusses a new technique where patients are able to grow new bones in a lab to help heal from injury, illness or surgery.
Biotech stocks were trading higher Thursday afternoon and reached the highest they have been since January 2016.
CNBC contributor Mike Khouw discusses why he sees Celgene as a "very attractive trade."
CNBC's Meg Tirrell reports on what can be the next big biotech takeover. The "Fast Money" traders weigh in.
Rep. Tammy Duckworth (D-IL) questions Mylan CEO Heather Bresch about school purchases of the EpiPen at her hearing on Capitol Hill.
Rep. Trey Gowdy (R-SC) questions Mylan CEO Heather Bresch about costs and compensation of the EpiPen and its generic equivalent at her hearing on Capitol Hill.
Rep. Gerald E. Connolly (D-VA) questions Mylan CEO Heather Bresch about EpiPen compensation at her hearing on Capitol Hill.
Rep. Scott Desjarlais (R-TN) questions Mylan CEO Heather Bresch about EpiPen compensation at her hearing on Capitol Hill.